Our Team

Our Team

We have assembled an experienced team with track records of success. Our team is well versed in development, manufacturing, commercial, operational, and corporate functions—each crucial for long-term growth and well-being of a successful pharmaceutical business. The executive team is supported by a talented board of directors.

Management Team


https://aruvant.com/wp-content/uploads/2019/11/will_017-scaled-e1574130068623-250x250.jpg
Will Chou, MD, MBA - Chief Executive Officer

Dr. Chou brings over 15 years of healthcare experience to Aruvant, and most recently served as Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy unit, where he led the global commercial launch of Kymriah, the first CAR-T cell therapy. Prior to that role, he led the Kymriah Lymphoma clinical development program to approvals in the North America, Europe and Asia. Prior to joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an M.B.A. from the Yale School of Management, an M.D. from the University of Pittsburgh School of Medicine, and an A.B. in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and a fellowship in geriatrics at Yale University.



https://aruvant.com/wp-content/uploads/2020/05/Joe-McIntosh_cropped2-scaled-250x250.jpg
Joseph McIntosh, MD - Chief Medical Officer

Dr. McIntosh brings over 16 years of drug development to Aruvant. He most recently served as Senior Vice President, Head of Clinical Development at PTC Therapeutics, where he was responsible for a portfolio of assets, including two gene therapies, across hematology, oncology and genetic rare diseases. Prior to that role, he was the Vice President of Development at PTC where he facilitated the approval of Translarna, PTC’s Duchenne muscular dystrophy asset. Before joining PTC, he worked in various development roles of increasing responsibility at NPS Pharmaceuticals, Eisai and Pfizer. Dr. McIntosh received his bachelor’s and medical degrees from University of Witwatersrand in South Africa.



https://aruvant.com/wp-content/uploads/2020/06/palani-250x250.jpg
Dr. “Palani” Palaniappan - Chief Technology Officer

Dr. Palaniappan joined Aruvant as chief technology officer in May of 2020 bringing 25 years of research and drug development experience including extensive work in chemistry, manufacturing and controls (CMC), a critical part of drug development. He most recent served as senior vice president, head of global technical operations and head of the Andover and Burlington sites at Sarepta. He was responsible for all stages of development from research through commercial for a portfolio of over 30 compounds using three modalities, antisense RNAs, gene therapy and gene editing. Prior to Sarepta, Dr. Palaniappan worked for over a decade at Takeda where he led teams based in the United States and Japan focused on CMC development and manufacturing of novel modality products including recombinant biologics, cell-based and live microbe products. Prior to joining Takeda, he worked in various development and product manufacturing roles of increasing responsibility at Millennium Pharmaceuticals which was acquired by Takeda, Biogen and Nexstar Pharmaceuticals which was acquired by Gilead. Dr. Palaniappan received his bachelor’s and master’s degree from Annamalai University of India. He earned his Ph.D. in Chemistry from the Indian Institute of Technology, Kanpur.

Dr. Palaniappan is supported by an experienced CMC team with a proven track record.


Board


https://aruvant.com/wp-content/uploads/2019/05/Torti_roivant_website-250x250.jpg
Frank Torti, MD - Chairperson of the Board

Frank Torti is the Vant Chair at Roivant Sciences. Dr. Torti serves as Chairman of the Board of the companies in the Roivant Pharma family and is responsible for the management of those businesses. He previously served as Vant Investment Chair, where he oversaw a group of companies responsible for the development of thirty-five investigational drugs in eleven therapeutic areas and over fifty clinical trials, including four successful Phase 3 trials. Dr. Torti joined Roivant in 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today.

Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics. Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School.



https://aruvant.com/wp-content/uploads/2020/01/VenkerLarge-e1542673331994-768x663-1-e1580414331896-250x250.jpg
Eric Venker, MD, PharmD - Board Member

Eric Venker serves as Chief Operating Officer of Roivant Sciences. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility, including Chief of Staff to the CEO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.